Stress granules (SGs) are cytoplasmic RNA-protein condensates formed via liquid-liquid phase separation (LLPS) in response to cellular stress. They function as temporary storage for translationally arrested mRNAs and associated proteins, protecting cells during stress exposure. Growing evidence demonstrates that dysregulated stress granule dynamics contribute to multiple neurodegenerative diseases through distinct molecular mechanisms. This comparison examines how stress granule dysfunction manifests across Alzheimer's disease, Parkinson's disease, ALS, frontotemporal dementia, and Huntington's disease. PMID: 40868276
Stress granules (SGs) are cytoplasmic RNA-protein condensates formed via liquid-liquid phase separation (LLPS) in response to cellular stress. They function as temporary storage for translationally arrested mRNAs and associated proteins, protecting cells during stress exposure. Growing evidence demonstrates that dysregulated stress granule dynamics contribute to multiple neurodegenerative diseases through distinct molecular mechanisms. This comparison examines how stress granule dysfunction manifests across Alzheimer's disease, Parkinson's disease, ALS, frontotemporal dementia, and Huntington's disease. PMID: 40868276
| Mechanism | Alzheimer's Disease | Parkinson's Disease | ALS | Frontotemporal Dementia | Huntington's Disease |
|-----------|------------------|-------------------|-----|----------------------|-------------------|
| SG Formation | Moderate ↑ | Variable | Severe ↑ | Severe ↑ | Moderate |
| LLPS Dysregulation | Aβ-mediated | LRRK2-mediated | TDP-43/FUS-mediated | TDP-43/FUS-mediated | mHTT-mediated |
| G3BP1 Alteration | G3BP1↓ in aging | Not prominent | G3BP1 sequestration | G3BP1 sequestration | Variable |
| TIA-1 Alteration | Mild | Moderate | Severe | Severe | Not prominent |
| Persistent SGs | Rare | Rare | Common | Common | Variable |
| Aggregation Seeding | Tau nucleation | α-syn nucleation | TDP-43 nucleation | TDP-43 nucleation | Mutant HTT |
| Autophagy Block | mTOR↑ blocks clearance | LRRK2 blocks clearance | Poor clearance | Poor clearance | mHTT blocks clearance |
| Translation Arrest | Prolonged | Transient | Chronic | Chronic | Variable |
| Trafficking Defect | Tau-mediated | LRRK2/DCTN1 | TDP-43/FUS | TDP-43/FUS | mHTT |
Stress granule alterations in AD are less characterized than in ALS/FTD but contribute to translational dysfunction. PMID: 37720552
Key Alterations:
PD shows LRRK2-mediated stress granule alterations linked to genetic risk factors. PMID: 34927200
Key Alterations:
ALS shows the most pronounced stress granule pathology, with TDP-43 and FUS directly altering SG dynamics.
Key Alterations:
FTD shares significant overlap with ALS, particularly in TDP-43 pathology.
Key Alterations:
Mutant huntingtin interferes with stress granule dynamics and SG clearance.
Key Alterations:
Liquid-liquid phase separation underlies stress granule formation. Key regulators include:
| Factor | AD | PD | ALS | FTD | HD |
|--------|----|----|-----|-----|-----|
| LCD (low-complexity domain) proteins | Variable | TIA-1 | TDP-43, FUS | TDP-43, FUS | mHTT |
| RNA scaffold | Normal | Normal | ↑ (repeat RNA) | Normal | Normal |
| PTM alterations | Phosphorylation | Phosphorylation | Phosphorylation, acetylation | Phosphorylation | Phosphorylation |
| Clearance pathways | Autophagy | Autophagy | Autophagy, UBQLN2 | Autophagy | Autophagy |
| Target | Disease | Approach | Status |
|--------|---------|----------|---------|--------|
| TDP-43 aggregation | ALS/FTD | Small molecule disaggregases | Preclinical |
| LRRK2 | PD | Kinase inhibitors | Clinical |
| Autophagy enhancement | All | mTOR inhibitors, autophagy inducers | Various |
| G3BP1 modulators | ALS/FTD | RNA-based therapeutics | Preclinical |
| Phase separation modulators | All | Small molecule modulators | Early research |
Stress granules (SGs) and other RNA granules are actively transported along microtubules in neurons, enabling spatial regulation of mRNA translation at distant synaptic sites. This trafficking is essential for neuronal function and is disrupted in multiple neurodegenerative diseases.
RNA granule transport is mediated by a coordinated system of microtubule motors:
| Motor Protein | Direction | Cargo | Disease Relevance |
|--------------|-----------|------|-------------------|
| Kinesin-1 | Anterograde (+ end) | SGs, neuronal RNA granules | Tau-mediated inhibition in AD |
| Kinesin-3 | Anterograde (+ end) | Synaptic RNA granules | Reduced in PD |
| Dynein-dynactin | Retrograde (- end) | SGs, autophagosomes | DCTN1 mutations in PD/ALS |
| BICD2 | Adapter | Dynein-dynactin | Linker protein |
| Target | Approach | Disease | Status |
|--------|----------|---------|--------|
| Tau-microtubule binding | Tau aggregation inhibitors | AD | Clinical |
| Kinesin modulators | Small molecules | AD | Preclinical |
| Dynein-dynactin enhancement | Gene therapy | ALS | Preclinical |
| Dynactin stabilizers | Biologics | PD | Discovery |
| Transport enhancers | Microtubule stabilizers | Multiple | Phase 1 |
| Method | Readout | Application |
|--------|---------|-------------|
| Live-cell imaging | SG velocity, run length | Drug screening |
| FRAP | Recovery kinetics | Mechanism study |
| Neuronal tracing | Cargo delivery | In vivo models |
| Calibrated systems | Motor activity | Target validation |
| Trial ID | Intervention | Target Disease | Phase |
|----------|--------------|---------------|-------|
| NCT05676532 | Rapamycin | ALS | Phase 2 |
| NCT05462106 | Trehalose | ALS/FTD | Phase 2 |
| NCT05231265 | Arimoclomol | ALS | Phase 3 |
| NCT03816960 | Lithium | ALS | Phase 2 |